Distributed paracrine signaling

Distributed paracrine signaling refers to a therapeutic mechanism where the clinical benefit is derived from the collective action of multiple secreted factors rather than a single discrete molecular interaction. This phenomenon is most prominently observed in regenerative medicine and cell-based therapies, such as those utilizing mesenchymal stem cells (MSCs), which release a diverse 'secretome' of cytokines, chemokines, and growth factors (Gnecchi et al., 2016, Circ Res). These factors act in concert to modulate the local microenvironment, influencing various cell types to suppress inflammation, promote angiogenesis, and stimulate endogenous tissue repair (Vizoso et al., 2017, Int J Mol Sci). Because the therapeutic effect is distributed across multiple pathways and cell types, this approach does not fit the traditional 'one drug, one target' pharmacological model. While this multi-faceted action allows for the treatment of complex, multifactorial diseases like osteoarthritis or graft-versus-host disease, it presents significant challenges for regulatory standardization and the development of precise potency assays (Liang et al., 2014, Stem Cells Int). Consequently, while highly effective in certain clinical contexts, the lack of a single molecular target necessitates a systems-biology approach to understand its full pharmacodynamic profile and ensure long-term safety.

Other names

Paracrine effectSecretome-mediated signalingBystander effectSystemic paracrine modulationNon-discrete molecular targeting

Simultaneous modulation of multiple signaling pathways via the secretion of a complex mixture of bioactive factors (cytokines, growth factors, and extracellular vesicles) that act on various neighboring cell types.